Market Closed -
Nasdaq
04:00:00 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
5.44
USD
|
-4.90%
|
|
+32.36%
|
+448.11%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
41.66
|
27.28
|
119.2
|
108.5
|
72.92
|
218.3
|
-
|
-
|
Enterprise Value (EV)
1 |
41.66
|
27.28
|
119.2
|
108.5
|
72.92
|
132.3
|
150.3
|
136.3
|
P/E ratio
|
-0.54
x
|
-1.31
x
|
-5.25
x
|
-1.43
x
|
-1.96
x
|
-4.44
x
|
-5.88
x
|
-4.05
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
10.6
x
|
34.5
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
7.32
x
|
21.5
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-5.83
x
|
-
|
-
|
-2.3
x
|
-2.24
x
|
-1.67
x
|
FCF Yield
|
-
|
-
|
-17.2%
|
-
|
-
|
-43.4%
|
-44.7%
|
-59.9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,208
|
5,866
|
8,352
|
33,583
|
36,828
|
40,135
|
-
|
-
|
Reference price
2 |
9.900
|
4.650
|
14.27
|
3.230
|
1.980
|
5.440
|
5.440
|
5.440
|
Announcement Date
|
9/10/19
|
10/13/20
|
9/15/21
|
9/15/22
|
9/14/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
20.55
|
6.33
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-25.94
|
-
|
-22.89
|
-41.84
|
-55.99
|
-65.4
|
-58.9
|
-84.04
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-286.6%
|
-1,327.73%
|
Earnings before Tax (EBT)
1 |
-30.45
|
-
|
-20.9
|
-41.06
|
-51.79
|
-63.17
|
-57.55
|
-85
|
Net income
1 |
-30.45
|
-20.33
|
-20.9
|
-41.06
|
-51.79
|
-63.33
|
-53.31
|
-85
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-259.44%
|
-1,342.82%
|
EPS
2 |
-18.50
|
-3.540
|
-2.720
|
-2.260
|
-1.010
|
-1.226
|
-0.9250
|
-1.342
|
Free Cash Flow
1 |
-
|
-
|
-20.44
|
-
|
-
|
-57.44
|
-67.14
|
-81.72
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-326.71%
|
-1,291.11%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/10/19
|
10/13/20
|
9/15/21
|
9/15/22
|
9/14/23
|
-
|
-
|
-
|
Fiscal Period: June |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
23
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-12.15
|
-10.75
|
-11.3
|
-10.22
|
-14.39
|
-17.14
|
-14.24
|
-15.91
|
-15.19
|
-16.21
|
-17.97
|
-17.38
|
-18.2
|
-19.15
|
37.58
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
163.37%
|
Earnings before Tax (EBT)
1 |
-12.59
|
-11.21
|
-9.423
|
-9.831
|
-13.56
|
-15.67
|
-12.73
|
-14.52
|
-13.91
|
-17.05
|
-18.15
|
-17.2
|
-18.1
|
-19.13
|
37.51
|
Net income
1 |
-12.59
|
-11.21
|
-9.423
|
-9.831
|
-13.56
|
-15.67
|
-12.73
|
-14.52
|
-13.91
|
-17.05
|
-18.15
|
-17.2
|
-18.1
|
-19.13
|
37.51
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
163.07%
|
EPS
2 |
-0.8000
|
-0.6500
|
-0.3000
|
-0.1900
|
-0.2600
|
-0.3000
|
-0.2500
|
-0.2800
|
-0.2700
|
-0.3400
|
-0.3200
|
-0.3250
|
-0.3250
|
-0.3225
|
-0.0350
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/9/22
|
5/12/22
|
9/15/22
|
11/9/22
|
2/10/23
|
5/11/23
|
9/14/23
|
11/13/23
|
2/13/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
86
|
68
|
82
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-20.4
|
-
|
-
|
-57.4
|
-67.1
|
-81.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.05
|
-
|
-
|
-
|
0.15
|
-
|
0.21
|
0.28
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
1.01%
|
4.35%
|
Announcement Date
|
9/10/19
|
10/13/20
|
9/15/21
|
9/15/22
|
9/14/23
|
-
|
-
|
-
|
Last Close Price
5.44
USD Average target price
10.57
USD Spread / Average Target +94.33% Consensus |
1st Jan change
|
Capi.
|
---|
| +448.11% | 218M | | +18.77% | 125B | | +14.05% | 108B | | -7.16% | 23.64B | | +3.38% | 22.39B | | -10.81% | 17.78B | | -41.74% | 16.43B | | -13.47% | 16.34B | | +2.23% | 13.56B | | +27.13% | 11.59B |
Bio Therapeutic Drugs
|